Ex­elix­is, Bris­tol-My­ers mount piv­otal study of Cabo/Op­di­vo com­bo for front­line kid­ney can­cer

Just days af­ter re­view­ing a promis­ing start com­bin­ing Bris­tol-My­ers Squibb’s check­point in­hibitor Op­di­vo (nivolum­ab) with Cabome­tyx (cabozan­ti­nib), Ex­elix­is is rolling out a late-stage part­ner­ship that will take the com­bo in­to a piv­otal Phase III study as a front­line ther­a­py for kid­ney can­cer. And not sat­is­fied with the one check­point tie-up, the South San Fran­cis­co-based biotech al­so an­nounced a deal this morn­ing to col­lab­o­rate with Roche on a com­bi­na­tion of its drug Tecen­triq (ate­zolizum­ab) and cabo.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.